Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 14 of 14 publications.

Pandya AG, Amoloja T, Bibeau K, DiBenedetti D, Kosa K, Butler K, Kornacki D, Ezzedine K. Assessing participants' experiences with vitiligo from patient interviews. Dermatol Ther. 2024 Sep;14(9):2467-78. doi: 10.1007/s13555-024-01241-w

Armstrong AW, Jayade S, Rege S, Joshi N, Patel V, Kalirai S, Wolin D, Boyle K, Patel D, Seigel L. Evaluating treatment choice in patients with moderate to severe psoriasis in the United States: results from a US patient survey. Dermatol Ther. 2024 Feb;14(2):421-39. doi: 10.1007/s13555-023-01089-6

Paller AS, Yosipovitch G, Weidinger S, DiBenedetti D, Whalley D, Gadkari A, Guillemin I, Zhang H, Eckert L, Chao J, Bansal A, Chuang CC, Delevry D. Development, psychometric validation and responder definition of worst itch scale in children with severe atopic dermatitis. Dermatol Ther. 2022 Dec;12(12):2839-50. doi: 10.1007/s13555-022-00804-z

Wyrwich KW, Winnette R, Bender R, Gandhi K, Williams N, Harris N, Nelson L. Validation of the alopecia areata patient priority outcomes (AAPPO) questionnaire in adults and adolescents with alopecia areata. Dermatol Ther. 2022 Jan;12(1):149-66. doi: 10.1007/s13555-021-00648-z

Simpson EL, de Bruin-Weller M, Bansal A, Chen Z, Nelson L, Whalley D, Prescilla R, Guillemin I, Delevry D. Definition of clinically meaningful within-patient changes in POEM and CDLQI in children 6 to 11 years of age with severe atopic dermatitis. Dermatol Ther. 2021 Aug;11(4):1415-22. doi: 10.1007/s13555-021-00543-7

Winnette R, Martin S, Harris N, Deal LS. Development of the alopecia areata patient priority outcomes instrument: a qualitative study. Dermatol Ther. 2021 Apr;11(2):599-613. doi: 10.1007/s13555-021-00508-w

Simpson EL, de Bruin-Weller M, Eckert L, Whalley D, Guillemin I, Reaney M, Chen Z, Nelson L, Qin S, Bansal A, Gadkari A. Responder threshold for Patient-Oriented Eczema Measure (POEM) and Children's Dermatology Life Quality Index (CDLQI) in adolescents with atopic dermatitis. Dermatol Ther. 2019 Dec;9(4):799-805. doi: 10.1007/s13555-019-00333-2

Kuznik A, Bego-Le-Bagousse G, Eckert L, Gadkari A, Simpson E, Graham CN, Miles L, Mastey V, Mahajan P, Sullivan SD. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther. 2017 Dec;7(4):493-505. doi: 10.1007/s13555-017-0201-6

Tell-Marti G, Puig-Butille JA, Potrony M, Plana E, Badenas C, Antonell A, Sanchez-Valle R, Molinuevo JL, Lleo A, Alcolea D, Fortea J, Fernandez-Santiago R, Clarimon J, Llado A, Puig S. A common variant in the MC1R gene (p.V92M) is associated with Alzheimer's disease risk. J Alzheimers Dis. 2017 Feb 3;56(3):1065-74. doi: 10.3233/JAD-161113

Brogan AJ, Deniz B, Miller JD, Mladsi DM, Herring WL, Thompson JR. Cost-effectiveness assessment of telaprevir combination therapy compared with pegylated interferon and ribavirin alone in the management of chronic hepatitis C virus infection in Canada. Poster presented at the 2012 Canadian Digestive Diseases Week and the Annual Winter Meeting of the Canadian Association for the Study of the Liver; February 24, 2012. Montreal, Canada. [abstract] Can J Gastroenterol. 2012 Feb; 26(Suppl(SA)).

Norton EC, Zarkin GA, Calingaert B, Bradley CJ. The effect of maternal substance abuse on the cost of neonatal care. Inquiry. 1996;33(3):247-57.